Citadel Advisors
DMK

Citadel Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Citadel Advisors’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,674
Closed -$37.9K – 15528
2023
Q1 		$37.9K Buy
+4,674
New +$62.1K ﹤0.01% 12483
2022
Q4 		– Sell
-2,085
Closed -$23.8K – 15670
2022
Q3 		$29K Buy
+2,085
New +$53.8K ﹤0.01% 11929
2022
Q2 		– Sell
-686
Closed -$21.4K – 14473
2022
Q1 		$27K Sell
686
-5,326
-89% -$229K ﹤0.01% 13159
2021
Q4 		$254K Buy
6,012
+4,715
+364% +$294K ﹤0.01% 11320
2021
Q3 		$88K Buy
1,297
+978
+307% +$71.6K ﹤0.01% 12996
2021
Q2 		$25K Sell
319
-1,930
-86% -$118K ﹤0.01% 13514
2021
Q1 		$148K Buy
+2,249
New +$175K ﹤0.01% 12059
2020
Q2 		– Sell
-1,374
Closed -$34K – 10675
2020
Q1 		$34K Buy
+1,374
New +$58.3K ﹤0.01% 9160
2019
Q3 		– Sell
-297
Closed -$27K – 9906
2019
Q2 		$27K Buy
+297
New +$36.1K ﹤0.01% 8896
2019
Q1 		– Sell
-633
Closed -$122K – 10042
2018
Q4 		$100K Sell
633
-433
-41% -$83K ﹤0.01% 8237
2018
Q3 		$261K Buy
1,066
+608
+133% +$144K ﹤0.01% 7805
2018
Q2 		$103K Sell
458
-712
-61% -$191K ﹤0.01% 8226
2018
Q1 		$287K Sell
1,170
-76
-6% -$19.9K ﹤0.01% 6819
2017
Q4 		$384K Buy
1,246
+987
+381% +$325K ﹤0.01% 6067
2017
Q3 		$95K Sell
259
-479
-65% -$170K ﹤0.01% 7056
2017
Q2 		$269K Buy
+738
New +$221K ﹤0.01% 6088
2017
Q1 		– Sell
-146
Closed -$36.8K – 8188
2016
Q4 		$32K Buy
+146
New +$29.3K ﹤0.01% 6978

Other funds holding DMK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cubist Systematic Strategies
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Harbour Investments
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Citadel Advisors's DMK Position: Q2 2023 in Review

Citadel Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 4,674 shares — an estimated $37.9K sold.

Citadel Advisors first reported a position in DMK in Q4 2016 and held it in 17 quarters. The position peaked at $384K in Q4 2017. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

  • Citadel Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,674 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $37.9K.
  • Citadel Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2016 and held it in 17 quarters.
  • Citadel Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $384K in Q4 2017.
  • 22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.